Dental Coverage Price Increases: Will They Hurt Sales Of Other Specialty Benefits?

Insurers are working harder to sell dental plans and other benefits to small and midsize U.S. employers.

Amy Friedrich, president of Principal Financial’s benefits and protection business, talked about the shift last week.

Friedrich said competition intensified for all of the products Principal offers through its specialty benefits division, including group life, group vision and group disability coverage, as well as group dental.

“Especially in the second half of 2024, we saw the market get a little more aggressive,” Friedrich said during a conference call with securities analysts. “We think that will continue in 2025. And the product where we’ve probably seen the most competitive pressure is dental.”

Meanwhile, Friedrich said, the plan participants’ are making more use of their dental benefits.

Principal responded by increasing dental coverage prices and getting tougher on dental plan underwriting.

“This has impacted some of the new sales in the back half of 2024, and it will impact, we think, at least the front half of 2025,” Friedrich said.

Principal’s dental plan sales fell to $31 million in the fourth quarter of 2024, from $35 million in the fourth quarter of 2023.

Friedrich warned that weaker dental benefits sales could hurt sales of some other types of benefits products, because dental insurance is usually sold as an important part of a specialty benefits product bundle.

Friedrich said accepting a temporary dip in sales is better than underpricing the coverage.

“Over the long term, disciplined underwriting for all of our products is really critical to building and maintaining profitable growth,” she said. “It’s critical to maintaining stable, predictable renewals, too.”

The earnings: Principal held the conference call to go over results for the fourth quarter with the analysts. The company reported in $902 million net income for the quarter on $4.1 billion in operating revenue, compared with an $839 million net loss on $4.2 billion in operating revenue for the fourth quarter of 2023.

Operating earnings, which exclude the effects of fluctuations in the value of investments and benefits, increased 2%, to $448 million.

The specialty benefits unit, which includes the dental insurance business, generated $147 million in pre-tax operating earnings on $824 million in revenue, up from $119 million in operating earnings on $791 million in revenue in the year-earlier quarter, in spite of a higher level of competition in the dental plan market.

The backdrop: Principal is the second insurer to mention lower dental benefits sales during its latest quarterly earnings call.

Executives from Aflac said their dental benefits sales were 33% lower in the latest quarter than in the fourth quarter of 2023. Aflac attributed its drop in dental benefits sales to problems with a system rollout.

 

Source Link

Recommended Articles

CMS Finalizes Major Changes To ACA Exchanges, Including Greater Access To Catastrophic Plans

Editor’s Note: Covered California is a State-Based Marketplace (SBM). For details on how these new rules will impact Covered California and other SBMs we recommend the following Princeton University linked report: (Broker rule changes appear at the bottom of the Princeton analysis.) https://shvs.org/wp-content/uploads/2025/06/SHVS_2025-Final-Marketplace-Integrity-Rule.pdf.   The Trump administration on Friday finalized a major rule reshaping the ...

Read More

Eroding ACA Enrollment Portends Higher Insurance Rates

Enrollment in the Affordable Care Act continues to erode as some customers struggle to make premium payments, with the declining numbers churning market uncertainty for insurers. In response, insurers are likely to raise rates again next year, following this year’s larger-than-typical hikes. Sign-ups were already down in January by about 1.2 million from last year’s record enrollment. For ...

Read More

White House Adds Generic Drugs To Direct-To-Consumer TrumpRx Site

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx, in a bid to expand a platform that is key to his administration’s efforts to lower prescription drug costs in the U.S. The administration is adding more than 600 generic drugs to the site, President Donald Trump said at an event ...

Read More

Supreme Court Rejects Big Pharma Appeals Challenging Negotiated Drug Prices In Medicare

The US Supreme Court on Monday rejected a series of appeals from several of the nation’s largest drugmakers challenging a program that is expected to save taxpayers and the federal government billions of dollars by requiring the companies to negotiate with Medicare on the prices for some of their most popular drugs. The court’s decision to deny ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square